BiotechTube

AZD1775

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uterine Cancer

Conditions

Uterine Cancer

Trial Timeline

Oct 22, 2018 → Jul 1, 2027

NCT ID
NCT03668340

About AZD1775

AZD1775 is a phase 2 stage product being developed by AstraZeneca for Uterine Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03668340. Target conditions include Uterine Cancer.

What happened to similar drugs?

4 of 18 similar drugs in Uterine Cancer were approved

Approved (4) Terminated (7) Active (8)
✅Elagolix + PlaceboAbbVieApproved
✅Mirena (BAY86-5028)BayerApproved
✅Tranexamic acid + Mefenamic acid + Placebo + Mirena (Levonorgestrel IUS, BAY86-5028)BayerApproved
✅Mifepristone tabletsChina Resources Pharmaceutical GroupApproved
🔄Relugolix Combination TabletSumitomo PharmaPhase 3
🔄Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for ElagolixAbbViePhase 3
🔄Estradiol/Norethindrone Acetate + ElagolixAbbViePhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT03668340Phase 2Active
NCT02610075Phase 1Completed

Competing Products

20 competing products in Uterine Cancer

See all competitors
ProductCompanyStageHype Score
AzenosertibZentalis PharmaceuticalsPhase 2
25
Amolimogene + AmolimogeneEisaiPhase 2/3
38
Relugolix Combination TabletSumitomo PharmaPhase 3
47
SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparationJiangsu Hengrui MedicinePhase 2/3
45
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
29
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
35
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for ElagolixAbbViePhase 3
40
Estradiol/Norethindrone Acetate + ElagolixAbbViePhase 3
40
Elagolix + PlaceboAbbVieApproved
43
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
35
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for ElagolixAbbViePhase 3
40
AdavosertibAstraZenecaPhase 2
35
Saizen® A + Saizen® BMerckPhase 3
40
Bintrafusp alfaMerckPhase 2
35
Pembrolizumab + LenvatinibMerckPhase 2
39
Pembrolizumab + Placebo for pembrolizumab + CisplatinMerckPhase 3
40
Pembrolizumab (Keytruda)MerckPhase 1
29
Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + OxaliplatinMerckPhase 2
35
Zoledronic acidNovartisPhase 2
27
KLH-2109 + LeuprorelinKissei PharmaceuticalPhase 3
40